TY - JOUR
T1 - Evaluation of reported claims of sex-based differences in treatment effects across meta-analyses
T2 - a meta-research study
AU - Kastrati, Lum
AU - Farina, Sara
AU - Valz Gris, Angelica
AU - Raeisi-Dehkordi, Hamidreza
AU - Llanaj, Erand
AU - Quezada-Pinedo, Hugo G
AU - Bally, Lia
AU - Muka, Taulant
AU - Ioannidis, John P A
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
PY - 2026/4
Y1 - 2026/4
N2 - Importance Differences in treatment effects between men and women may have important implications across diverse interventions and diseases. Objectives We aimed to evaluate claims of sex-based differences in treatment effects across published meta-analyses. Eligibility criteria Published meta-analyses of randomised controlled trials (RCTs) that had any mention of sex (male/female) subgroup or related analysis in their abstract Information sources PubMed (searched up to 17 January 2024). Synthesis We determined how many meta-analyses had made claims of sex-based differences in treatment effects. These meta-analyses were examined in depth to determine whether the claims reflected sex-treatment interactions with statistical support or fallacious claims, and we categorised the frequency of different fallacies or genuine interactions. We also investigated how many of the genuine and fallacious claims were considered and discussed in Up-To-Date. Whenever possible, we reanalysed the p value for sex-treatment interaction. Main outcomes and measures Number of claims with statistical support and fallacious claims; clinical implications of subgroup differences as well as the credibility of subgroup analyses assessed by the Instrument to assess the Credibility of Effect Modification Analyses criteria. Results 216 meta-analysis articles fulfilled the eligibility criteria. Of them, 99 stated in the abstract that there was no sex-based difference, and 20 mentioned a sex-based subgroup analysis but without reporting results in the abstract. The other 97 meta-analyses made 115 claims of sex-based differences. 27 of the 115 positive claims for subgroup differences made across 21 articles had statistical support at p<0.05, of which 4 were mentioned in Up-To-Date, with none leading to different recommendations for men and women. 39 of the 115 positive claims made across 35 articles were fallacious, where the sex-treatment interaction was not statistically significant. The most common form of fallacy (29/115) was made in instances where there was a significant effect in one sex, but not in the other, with no true difference between the two groups. In 7/115 other claims, there were larger effects in one sex, again, with no true difference between the two groups, and 3/115 other claims had various forms of fallacies. Another 44 articles made 49 claims based on potentially fallacious methods (44 based on meta-regression, and 5 provided the results of only one group), but proper data were unavailable to assess statistical significance. Conclusions and relevance Few meta-analyses of RCTs make claims of sex-based differences in treatment effects, and most of these claims lack formal statistical support. In the present sample, statistically significant and clinically actionable sex-treatment interactions were rare.
AB - Importance Differences in treatment effects between men and women may have important implications across diverse interventions and diseases. Objectives We aimed to evaluate claims of sex-based differences in treatment effects across published meta-analyses. Eligibility criteria Published meta-analyses of randomised controlled trials (RCTs) that had any mention of sex (male/female) subgroup or related analysis in their abstract Information sources PubMed (searched up to 17 January 2024). Synthesis We determined how many meta-analyses had made claims of sex-based differences in treatment effects. These meta-analyses were examined in depth to determine whether the claims reflected sex-treatment interactions with statistical support or fallacious claims, and we categorised the frequency of different fallacies or genuine interactions. We also investigated how many of the genuine and fallacious claims were considered and discussed in Up-To-Date. Whenever possible, we reanalysed the p value for sex-treatment interaction. Main outcomes and measures Number of claims with statistical support and fallacious claims; clinical implications of subgroup differences as well as the credibility of subgroup analyses assessed by the Instrument to assess the Credibility of Effect Modification Analyses criteria. Results 216 meta-analysis articles fulfilled the eligibility criteria. Of them, 99 stated in the abstract that there was no sex-based difference, and 20 mentioned a sex-based subgroup analysis but without reporting results in the abstract. The other 97 meta-analyses made 115 claims of sex-based differences. 27 of the 115 positive claims for subgroup differences made across 21 articles had statistical support at p<0.05, of which 4 were mentioned in Up-To-Date, with none leading to different recommendations for men and women. 39 of the 115 positive claims made across 35 articles were fallacious, where the sex-treatment interaction was not statistically significant. The most common form of fallacy (29/115) was made in instances where there was a significant effect in one sex, but not in the other, with no true difference between the two groups. In 7/115 other claims, there were larger effects in one sex, again, with no true difference between the two groups, and 3/115 other claims had various forms of fallacies. Another 44 articles made 49 claims based on potentially fallacious methods (44 based on meta-regression, and 5 provided the results of only one group), but proper data were unavailable to assess statistical significance. Conclusions and relevance Few meta-analyses of RCTs make claims of sex-based differences in treatment effects, and most of these claims lack formal statistical support. In the present sample, statistically significant and clinically actionable sex-treatment interactions were rare.
KW - Methods
KW - Systematic Reviews as Topic
KW - Women's Health
UR - https://www.scopus.com/pages/publications/105008804950
U2 - 10.1136/bmjebm-2024-113359
DO - 10.1136/bmjebm-2024-113359
M3 - Article
C2 - 40537175
SN - 2515-446X
VL - 31
SP - 114
EP - 124
JO - BMJ Evidence-Based Medicine
JF - BMJ Evidence-Based Medicine
IS - 2
ER -